Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accounts Payables (2016 - 2025)

China Pharma Holdings' Accounts Payables history spans 16 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 17.41% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 17.41%, while the annual FY2025 figure was $2.6 million, 17.41% up from the prior year.
  • Accounts Payables reached $2.6 million in Q4 2025 per CPHI's latest filing, up from $588739.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $2.8 million in Q1 2021 to a low of $327033.0 in Q4 2021.
  • Average Accounts Payables over 5 years is $1.4 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: tumbled 88.1% in 2021, then skyrocketed 328.13% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $327033.0 in 2021, then skyrocketed by 103.98% to $667082.0 in 2022, then skyrocketed by 44.87% to $966420.0 in 2023, then surged by 125.88% to $2.2 million in 2024, then rose by 17.41% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Accounts Payables are $2.6 million (Q4 2025), $588739.0 (Q3 2025), and $2.3 million (Q2 2025).